

Medicines Advisory Group

Date/Time: Wednesday 31st January 2018, 12-2pm
Location: Rheumatology Seminar Room, King Edward Building, BRI (location B4-025)

[MAG workspace](#) [BNSSG Formulary](#)
[Implementing NICE guidance workspace](#)

AGENDA

Items may be taken out of sequence to better suit the clinical commitments of presenters

Item	Agenda Item			Presented	Papers
1.	Welcome and apologies Apologies:				-
2.	Minutes: November 2017				✓
3.	Matters arising from 22nd November 2017				
3.1	Biosimilar policy				✓
3.2	Immunoglobulin policy final version to be re-circulated following trial of Medway proforma				✓
3.3	Options appraisal for immunoglobulin panel				✓
4.	Strategic issues: CQUIN; BNSSG Sustainability & Transformation Programme; Financial recovery;				
4.1	CQUIN Q2 update			JC	✓
4.2	MO STP update			JS	-
4.3	Medicines Finance update			JS	-
4.4	NHS E Circulars			JC	✓
5.	BNSSG Joint Formulary group: Decisions and matters arising				
5.1	November decisions			JC	✓
6.	BNSSG Area Therapeutics committee: Decisions and matters arising				
	Self care guidance			JC	✓
7.	New UHBristol formulations and exceptional funding: Applications received				
7.1	New drug request				
	Formulation	Indication	Requested by		
	Burosumab	X-Linked hypophosphatemia (XLH)		13.30	✓
	Gluteraldehyde	Cardiac surgery		RW	✓
	Sulphur hexafluoride microbubbles (SonoVue)	Diagnosis of peripheral artery disease		13.15	✓
7.2	Individual Funding Applications: For review pre-submission				
	Formulation	Indication	Requested by		
	Calcium mefolinate	Methylenetetrahydrofolate reductase deficiency (MTHFR Deficiency). Co-morbidities: Learning difficulties, spasticity		GP/WB 12.50	✓
7.3	Individual Funding Applications: For retrospective review				
	Formulation	Date submitted	Indication	Requested by	
	Pembrolizumab	17/11/2017 (refused)	Extranodal NK/T cell lymphoma		✓
	Ribavirin IV	20/11/2017 (approved)	RSV		✓
	Eltrombopag	21/12/2017 (refused)	Severe Aplastic anaemia		✓

	Nintedanib	03/01/2018 (pending)	Clear cell ovarian cancer		✓	
	Inflectra	29/01/2018 (pending)	Acute uveitis			
	Abiraterone	30/01/2018 (pending)	Metastatic prostate cancer. Adverse effects to Enzalutamide			
7.4	IFR interventions previously discussed.					
7.5	Compassionate Use Drugs/Patient Access Schemes					
	Formulation	Indication	Notes		✓	
	Neratinib Patient Access Scheme	Breast Cancer				
7.6	Early Access Scheme Drugs					
7.7	Applications for One-off Drugs					
	Formulation	Indication	Requested by		13.00	✓
	Citrasate haemodialysis fluid	Dialysis fluid				
7.8	Applications for self-funding – Blinotumumab (retrospective review)					
8.	Clinical guidelines and documentation					
	Nil					
9.	Immunoglobulin assessment panel					
9.1	Grey or black indications for IFR approval.					
9.2	Grey indications for internal approval: Systemic vasculitides and ANCA disorders					
9.3	Blue indications for authorisation.					✓
10.	Homecare medicines					
	Dupilimab EAMs homecare charge					
11.	Medicines optimisation & cost-effective prescribing					
12.	NICE					
	Verbal update, NG 82: Treatment of Wet Age-related Macular Degeneration					-
13.	Any other business					
	EPMA update					✓
	Glutaraldehyde 0.6%					

Future meeting dates – 2018

Please note change of week to avoid BNSSG D&TC clashes

21 March	12:00 to 14:00	Board room, THQ
30 May	12:00 to 14:00	Conference room, THQ
18 Jul	12:00 to 14:00	Board room, THQ
26 Sep	12:00 to 14:00	Board room, THQ
28 Nov	12:00 to 14:00	Board room, THQ

Medicines Advisory Group

Date/Time: 31st January 2018, 12noon to 2pm
Location: Rheumatology Seminar Room, Level 4
KEB

[MAG workspace](#)
[Meeting documents](#)

Minutes

1. Welcome and Apologies

welcomed all to the meeting

Present:

Acting Chair & Director of Pharmacy, Clinical Pharmacy Manager, Interface Pharmacist Bristol CCG, NICE Manager, High Cost Drugs Pharmacist, Consultant Paediatric Oncologist, Consultant Nurse Emergency Department, Consultant Intensive Care.

Apologies: Interim Medical Director, Consultant STMH, Cardiology representative

2. Minutes of the meeting held 22nd November 2017

The minutes were accepted as a true and accurate record.

3. Matters arising

- 3.1 Biosimilar Policy – change to be made for process relating to patients switching back to the originator.
- 3.2 Immunoglobulin policy, no comments raised
- 3.3 IVIG Panel options. Agreed a local panel to be formed in the interim, using Paediatric Immunologist. Await NHS England local IVIG multi-Trust panel set up.

4. Strategic Issues

4.1 MO CQUIN Q2

Passed Q2 (letter in papers); Q3 data submitted.

Concerns about achieving Q4 target due to difficult new targets for SACT data; and introduction of etanercept biosimilar at BRCH.

4.2 Medicines Optimisation STP update

Meeting held last week. Projects reviewed, focus for the work to be decided.

Secondary care Trusts leading on High Cost Drug and Digital Innovation work streams.

4.3 Medicines Finance update

Close to achieving 17/18 CIP stretch target.

18/19 CIP target set, communication to be sent to directorates looking for any medicines-related CIP ideas to achieve the target.

4.4 NHSE Specialised Commissioning Circulars

List of circulars stated for information purposes.

5. BNSSG Joint Formulary Group (JFG) update
November decisions stated for information purposes

6. BNSSG Area Therapeutics Committee

- CCG Self-care guidance reviewed, discussed the implications for A+E and day-case surgery
- Gluten-free CCG guidance currently out for consultation, guidance to be circulated at UHB

7. New Formulations and exceptional funding

Type of request	Formulation	Indication	Requested by	Date of IFR	Decision
New drug request	Burosumab	X-Linked hypophosphatemia (XLH)			Use approved
New drug request	Gluteraldehyde	Cardiac surgery			Refer to Clinical effectiveness Committee
New drug request	Citrasate haemodialysis fluid	Dialysis fluid			Use approved
New drug request	Sulphur hexafluoride microbubbles (SonoVue)	Diagnosis of peripheral artery disease			Use approved for use in feasibility study
IFR	Calcium mefolinate	Methylenetetrahydr ofolate reductase deficiency (MTHFR Deficiency). Co-morbidities: Learning difficulties, spasticity			Submit IFR
IFR	Pembrolizumab	Extranodal NK/T cell lymphoma		17/11/2017 (refused)	Reviewed
IFR	Ribavirin IV	RSV		20/11/2017 (approved)	Reviewed
IFR	Eltrombopag	Severe Aplastic anaemia		21/12/2017 (refused)	Reviewed
IFR	Nintedanib	Clear cell ovarian cancer		03/01/2018 (pending)	Reviewed
IFR	Inflectra	Acute uveitis		29/01/2018 (pending)	Reviewed
IFR	Abiraterone	Metastatic prostate cancer.		30/01/2018 (pending)	Reviewed
Compassionate use drugs	Neratinib Patient Access Scheme	Breast Cancer			Patient already in scheme, to continue at UHB, with clarification for the patient on the possibilities at the end of the scheme

8. Clinical guidelines and documentation

Nil

9. Immunoglobulin Assessment Panel

9.1 Grey indication presented

9.2 Blue short term indications reviewed

10. Homecare

Dupilimab, homecare arrangement returned to the homecare company to clarify costs.

11. Medicines optimisation and cost-effective prescribing

12. NICE

updated the group on recently issued [NICE appraisals](#).

13. AOB

Electronic prescribing – update on roll-out and next steps. Need to explore the way in which decisions about EPMA roll out are made, as clinical input is required. Risk of reduced completion of DVT risk assessment raised.

MAG Action Log 31/01/2018

Agenda Item	Action	Responsibility	Completion date
3.1	Biosimilar policy – change switch back process		
3.3	IVIG panel, set up an interim panel		
6	Circulate CCG GF guidance		
7.1	Gluteraldehyde, intervention to be referred to Clinical Effectiveness Committee		
Nov	During revision of trust 'top-up' policy, to ensure process clear for referral of all self-funding requests to MAG		
Nov	High cost drugs policy to be split into smaller policies and re-circulated to MAG for comment		
Nov	Pharmacy webpage to be reviewed to include links to trust policies held on DMS		

Future meeting dates – 2018		
<i>Please note change of week to avoid BNSSG D&TC clashes</i>		
21 March	12:00 to 14:00	Board room, THQ
30 May	12:00 to 14:00	Conference room, THQ
18 Jul	12:00 to 14:00	Board room, THQ
26 Sep	12:00 to 14:00	Board room, THQ
28 Nov	12:00 to 14:00	Board room, THQ